Skip to main content
logo
Braveheart Bio, Inc. (BRVE)
NASDAQ: BRVE · Real-Time Price · USD
23.00
-0.61 (-2.58%)
Sep 23, 2026, 10:54 AM EDT - Market open

Braveheart Bio Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025
Period Ending
Jun '26 Dec '25
Cash & Equivalents
122.8389.16
Cash & Short-Term Investments
122.8389.16
Cash Growth
--
Prepaid Expenses
0.610.12
Total Current Assets
123.4589.28
Other Long-Term Assets
0.070.07
Total Assets
126.9689.35

Liabilities

Fiscal Year
TTMFY 2025
Period Ending
Jun '26 Dec '25
Accounts Payable
2.671.06
Accrued Expenses
5.351.18
Other Current Liabilities
0.663
Total Current Liabilities
9.065.24
Other Long-Term Liabilities
0.090.09
Total Liabilities
9.345.33

Shareholders' Equity

Fiscal Year
TTMFY 2025
Period Ending
Jun '26 Dec '25
Common Stock
00
Additional Paid-In Capital
-0.18
Retained Earnings
-95.91-66.05
Total Common Equity
-95.91-65.87
Shareholders' Equity
117.6184.02
Total Liabilities & Equity
126.9689.35

Additional Metrics

Fiscal Year
TTMFY 2025
Period Ending
Jun '26 Dec '25
Net Cash (Debt)
122.2689.16
Net Cash Growth
--
Net Cash Per Share
18.2323.22
Filing Date Shares Outstanding
82.456.69
Total Common Shares Outstanding
8.356.69
Working Capital
114.3984.04
Book Value Per Share
-11.48-9.85
Tangible Book Value
-95.91-65.87
Tangible Book Value Per Share
-11.48-9.85
SEC Filings: 10-K · 10-Q